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Abstract: A high-resolution magic angle spinning NMR spectroscopic approach is presented for evaluating the occurrence, amount 
and aggressiveness of cancer in human prostate tissue samples. Using this technique, key metabolites in malignant and non-malignant 
samples (n = 149) were identified, and patterns of their relative abundance were analyzed by multivariate statistical methods. Ratios of 
various metabolites – including (glycerophophorylcholine + phosphorylcholine)/creatine, myo-inositol/scyllo-inositol, scyllo-inositol/
creatine, choline/creatine, and citrate/creatine – correlated with: i) for non-malignant tissue samples, the distance to the nearest tumor 
and its Gleason score and; ii) the fraction of tumor cells present in the sample; and iii) tumor cell proliferation (Ki67 labelling index). 
This NMR-based approach allows the extraction of information that could be useful for developing novel diagnostic methods for pros-
tate cancer.
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Introduction
Prostate cancer (PCa) is among the most common 
cancers  diagnosed  worldwide.1  The  course  of  the 
  disease is highly variable and very difficult to   predict 
at  diagnosis  using  currently  available  techniques.2 
New  diagnostic  procedures  are  urgently  needed 
that  can  accurately  detect  non-palpable  tumors,3 
increase  biopsy  sensitivity,  differentiate  between 
clinically  significant  and  non-significant  variants, 
and  direct  biopsies  towards  the  most  malignant 
foci.4,5  Innovative  diagnostic  approaches  that  can 
meet these requirements are being developed using 
ex-vivo  High  Resolution  Magic  Angle  Spinning 
(HRMAS) NMR,6–8 and in-vivo magnetic resonance 
spectroscopic  imaging  (MRSI).9,10  Since  it  is 
  non-destructive, samples analyzed by HR-MAS NMR 
can be subsequently examined histopathologically.11–13 
Hence, HRMAS NMR-derived scores for metabolic 
biomarkers can be correlated with standard patho-
logical diagnostics such as the Gleason score,14 and 
immunohistochemically-scored  prognostic  markers 
such as the Ki67 proliferation index.7,13 The results 
can then be used to guide and assist interpretation of 
results of in-vivo magnetic resonance spectroscopic 
imaging (MRSI)15 for clinical studies.
Here,  we  provide  evidence  that  HRMAS  NMR 
measurements of (glycerophophorylcholine +    phos-
phorylcholine)/creatine (GPCho + PCho)/Cre), myo-
inositol/scyllo-inositol (m-Ino/s-Ino), scyllo-inositol/
creatine (s-Ino/Cre) and choline/creatine (Cho/Cre) 
ratios correlate to the fraction of tumor cells in pros-
tate specimens. The method can also provide indi-
cations of tumor aggressiveness and the distance of 
samples from the nearest tumor. Hence, it may have 
substantial diagnostic potential.
Materials and methods
Source of material and preparation
Samples (149; 108 non-malignant and 41 malignant) 
obtained from 40 patients (n = 2–20 samples from each 
patient) who had undergone radical prostatectomy for 
PCa were included in this study. The ages of the patients 
were 60 ± 5.5 yrs (Mean ± SD; range 41–71 yrs). The 
pathological tumor stage (pT) ranged from 1 to 3 and 
their  serum  prostate-specific  antigen  (PSA)  levels 
were 12.4 ± 13.5 (Mean ± SD) ng/mL (range 3.0–50). 
The tumors were all Gleason score 6–7; GS 6 (3 + 3) 
n = 27, and GS (3 + 4) n = 14. The patients had not 
received any anti-cancer treatment prior to surgery. 
Directly after surgery each specimen was chilled on 
ice. At pathology prostate surfaces were inked and 
the prostates were cut into approximately 1-cm thick 
horizontal sections. From these sections 2–20   samples 
were  punched  from  the  peripheral  zone  of  each 
  prostate. The punches (0.5 cm in diameter and about 
1 cm long) were snap-frozen in liquid nitrogen within 
30 minutes of surgical removal of the prostate and 
thereafter stored at −70 °C. The prostate slices were 
fixed in formalin, embedded in paraffin and cut into 
5-µm thick   sections. The sections were then stained 
with hematoxylin and eosin and all tumor foci were 
identified by microscopy and marked on the whole-
mount  sections.  The  origin  of  each  frozen  punch 
could thus be identified on the whole-mount sections 
as round holes and preliminarily classified as malig-
nant or non-malignant tissue, depending on the type 
of tissue seen in the immediate surroundings. From 
each frozen punch a small sample was randomly cut 
and analyzed by HRMAS as described below. After 
HRMAS each analyzed sample was fixed in formalin, 
embedded in paraffin, cut into 5 µm thick sections, and 
immunostained for high molecular weight cytokeratin 
(cytokeratin-hmw,  DAKO,  Stockholm,  Sweden)  or 
the cell proliferation marker Ki67 (DAKO) as pre-
viously described,16 using standard histopathological 
  procedures. In these sections the percentage of tumor 
tissue (glands lacking cytokeratin-hmw positive basal 
epithelial  cells)  and    non-malignant  tissue  (glands 
with  an  intact  basal  epithelial  cell  layer)  and  the 
tumor Gleason score were determined. The fraction 
of malignant vs.   non-malignant tissue in each sample 
was determined by using a light microscope with a 
square-lattice mounted in the eye-piece to count the 
number of grid-intersections falling on each tissue 
compartment, as previously described.17 The distance 
between each sample of non-malignant prostate tissue 
and the closest tumor was also measured on the whole 
mount sections of the prostates. The study design was 
approved by the review board for human studies in 
Umeå, Sweden.
1h hrMAS nMr experiments
NMR spectroscopy was performed using an AMX2 
NMR spectrometer operating at a  1H frequency of hrMAS nMr analysis of intact Pca tissues
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500.13 MHz, equipped with a HRMAS dual band 
(1H and  13C) probe and 4 mm zirconia rotors with 
spherical inserts and Kel-F caps (all from Bruker 
Biospin  GMBH,  Karlsruhe,  Germany).  All  pros-
tate specimens were cut into 15 ± 5 mg portions 
using a surgical steel blade to fit the rotors, 10 µl 
of D2O was added to each specimen for  2H field 
locking,  then  the  samples  were  packed  in  rotors 
and  either  immediately  analyzed  or  temporarily 
stored at −20 °C. All samples were treated as identi-
cally as possible to minimize handling errors, and 
spun at constant room temperature (20 °C), at 5 kHz 
and the magic angle (54.7°). A rotor-synchronized 
Carr-Purcell-Meibom-Gill (CPMG) pulse sequence, 
90°-(τ-180°-τ)n-acquisition,18  with  a  T2  filter  of 
20 ms duration was used to suppress broad signals 
from macromolecules. Each spectrum was recorded 
with 256 transients, using 16 K complex time domain 
data points and a spectral width of 10309 Hz at a 
repetition time of 5.0 seconds. Water signals were 
suppressed  with  a  presaturation  pulse  during  the 
relaxation delay prior to the CPMG pulse sequence. 
All 1D spectra were generated at a maximum time 
of 30 minutes.
Spectral processing
All NMR spectra were processed using   MestReNova 
6.0.4  (Mestrelab  Research,  A  Coruña,  Spain). 
The  free  induction  decays  (FID’s)  of  the  CPMG-
edited  1H  HRMAS  spectra  were  subjected  to  a 
1.5  Hz  exponential  multiplication  prior  to  Fourier 
  transformation. The spectra were referenced to the 
residual water peak by setting the chemical shift of 
the lactate doublet equal to exactly 1.33 ppm.
Statistics
Lactate and alanine signals from the prostate   samples 
were  found  to  be  somewhat  unstable,19  possibly 
due to oxidation in contact with air, and their lipid 
contents were found to be highly variable, thus these 
substances  were  excluded  from  further  analysis. 
  However, HRMAS NMR integrals indicating levels 
of (GPCho + PCho), choline, citrate, creatine, taurine, 
myo-inositol and scyllo-inositol were more   constant. 
Summary statistics for these variables (means and SD) 
were calculated using SPSS v. 16.0 (SPSS, Chicago, 
IL,  USA).  Relationships  between  these  potentially 
predictive  variables  and  the  cancer  status  of  the 
samples were then examined using STATA (v. 10, 
StataCorp LP, College Station, TX, USA), in which 
the  data  were  initially  standard  error-adjusted,  to 
take   dependencies between samples originating from 
the same patient (clustering) into consideration. The 
ability of Cit/Cre, m-Ino/s-Ino, and Cho/Cre ratios 
to  discriminate  between  prostate  tissue  specimens 
(malignant and non-malignant) with Gleason scores 
of 6 (3 + 3) and 7 (3 + 4) was assessed by binary 
logistic  regression.  In  addition,  multivariate  linear 
regression was then applied to assess the relationships 
between: the tumor fraction in the tissue samples (% 
cancer), where the tumor fractions were grouped into 
bins of; 0%, 20%, 40%, 60%, 80%, and 100%, dis-
tance to tumor, and Ki67 (dependent variables), and 
the following metabolic ratios: (GPCho + PCho)/Cre, 
Cho/Cre, m-Ino/s-Ino, and s-Ino/Cre. When employ-
ing tumor fraction bins as dependent the predictors 
corresponding metabolic mean ratios were used. In 
all of these analyses, P-values  0.05 were consid-
ered to be statistically significant.
Results
1h hrMAS nMr spectra  
of prostate tissues
As shown in Figure 1, well-resolved 1D 1H HRMAS 
NMR spectra were obtained from the prostatectomy 
material (within 30 minutes for each   spectrum). None 
of the samples appeared to be adversely affected by 
the fast spinning rate and they could be successfully 
examined  by  histopathology  post  HRMAS  NMR. 
Various  metabolites  were  detected  in  the  NMR 
spectra of non-malignant (Fig. 1A) and malignant 
prostate  tissues  (10%  malignant,  Fig.  1B;  100% 
malignant,  Fig.  1C;  corresponding  morphological 
pictures are presented on the left side of each NMR 
spectrum),  as  indicated,  including:    lactate  (1.33 
ppm), alanine (1.48 and 3.78 ppm), glutamate (2.05, 
2.15, and 2.35 ppm), glutamine (2.14 and 2.47 ppm), 
citrate  (2.55  and  2.65  ppm),  diallylic    protons 
(  omega-6,20  2.80  ppm),  creatine  (3.02  and  3.94 
ppm), polyamines (3.05–3.15 ppm), choline (3.20 
ppm), glycerophosphorylcholine + phosphorylcho-
line (GPCho + PCho, 3.22 ppm), taurine (3.25 and 
3.46 ppm),   myo-inositol (3.29 and 3.52–3.62 ppm) 
and scyllo-inositol (3.35 ppm).Stenman et al
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The NMR spectra contained quantitative informa-
tion about the metabolites present in the examined 
prostate tissues. Basic descriptive data are presented 
in Table 1.
Further analysis of these data detected the correla-
tions between the NMR-acquired information and the 
following cancer-related parameters:
gleason scores
Binary multivariate logistic regression was used to 
assess the ability of NMR-measured metabolite ratios 
to differentiate between tumors with   Gleason scores 
of  6  and  7.  For  malignant    tissues,  no  single  ratio 
had significant discriminatory power in this respect 
(P = 0.081 and OR 0.08 for the Cit/Cre ratio, the stron-
gest predictor). In   contrast, for   non-malignant tissue 
samples (taken at   various   distances from the tumor) 
m-Ino/s-Ino and Cho/Cre ratios were both strongly 
related to the tumor   Gleason score (OR 0.22, 95% CI 
0.09–0.57, P = 0.002 and OR 12.8, 95% CI 3.57–45.75, 
P , 0.001, respectively). Mean values of metabolite 
ratios for both malignant and non-malignant   prostate 
tissue specimens with Gleason Scores of 6 vs. GS 7 
are presented in Table 2.
Tumor cell fractions in the samples
We  have  previously  shown  that  HRMAS  NMR- 
derived  bio-markers  can  be  used  to  discriminate 
between  malignant  and  non-malignant    prostate 
  tissue.21 As individual prostate needle biopsies often 
  contain mixtures of both non-malignant and malignant 
  tissue we have now examined the power of HRMAS 
NMR to determine the   fraction of cancerous tissues 
in a mixed sample. The   multivariate linear regression 
analysis demonstrated that the (GPCho + PCho)/Cre, 
Cre
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Figure 1. representative  1h MAS nMr spectra of A) non-malignant; 
B) 10% malignant; c) 100% malignant human prostate tissue samples 
obtained from a 67-year-old patient with a serum PSA of 50 and a gS 
7(3 + 4) stage 3 tumor. Inserted micrographs: To distinguish malignant 
and non-malignant glands the sections were immuno-stained to   visualize 
basal  epithelial  cells  (dark)  lining  non-malignant  glands.  A)  100% 
  non-malignant prostate tissue sample with corresponding morphology. 
All glands are lined with a basal cell layer and are thus non-malignant;   
B) Malignant prostate sample containing 10% tumor and 90%   non- malig-
nant tissue. The malignant glands, seen in the middle left constitute 10% 
of the whole sample and lack basal cells; c) Prostate   sample   containing 
100% cancer. In this specimen no basal cells can be seen. 
note: *contaminant.
Table 1. Mean metabolite ratios (±SD) of non-malignant 
and malignant prostate tissue samples.
Variable Diagnosis n Mean sD
Age non-malignant 108 60.36 5.59
Malignant 41 59.37 5.41
Ki67 non-malignant 108 0.04 0.30
Malignant 37 3.91 3.70
PSA non-malignant 108 12.19 14.02
Malignant 40 12.83 12.39
Distance to  
tumor
non-malignant 
Malignant
108 
41
1.00 
0.00
1.01 
0.00
Fraction of  
tumor in %
non-malignant 
Malignant
108 
41
0.00 
41.85
0.00 
33.60
Myo-lno/cre non-malignant 108 0.42 0.26
Malignant 41 0.45 0.18
(gPcho + Pcho)/ 
cre
non-malignant 
Malignant
108 
41
0.86 
1.42
0.26 
0.70
cho/cre non-malignant 108 1.15 0.52
Malignant 41 1.93 1.87
cit/cre non-malignant 108 1.36 0.74
Malignant 41 1.35 0.65
Myo-lno/ 
scyllo-lno
non-malignant 
Malignant
108 
41
5.65 
4.98
1.59 
1.75hrMAS nMr analysis of intact Pca tissues
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m-Ino/s-Ino,  Cho/Cre,  and  s-Ino/Cre  mean  ratios 
correlated with the tumor fraction (tumor load), in the 
specimens (R2 = 0.45, P , 0.05; Table 3). The correla-
tion of the most strongly related ratio, (GPCho + PCho)/
Cre, with tumor load is   displayed in Figure 2. It should 
be noted that specimens containing a particular fraction 
of tumor tissue showed substantially higher inter-sam-
ple variations in spectral values of (GPCho + PCho)/
Cre, than non-malignant tissue samples (Fig. 2).
The  morphology  of  non-malignant  samples 
was  however  highly  variable,  eg,  with  respect  to 
  fractions of stroma and epithelium, the presence of 
inflammatory cells and glandular morphologies (atro-
phic or not). Such differences apparently had only 
moderate effects on the spectra derived from non-
malignant tissue.
number of proliferating cells
The metabolite ratio (GPCho + PCho)/Cre in tumor 
tissue correlated not only with tumor load, as described 
above, but also with the proliferation marker Ki67 
(b = 1.97, SE b = 0.47, 95% CI 1.02–2.92, R2 = 0.15, 
P , 0.001).
Distance to the nearest tumor
The distance to the nearest tumor was jointly correlated 
with the m-Ino/s-Ino and (GPCho + PCho)/Cre ratios 
(R2 = 0.09), with the following parameters: m-Ino/s-
Ino, b = 0.10, SE b = 0.04, 95% CI 0.01–0.18, P = 0.03; 
(GPCho + PCho)/Cre, b = −0.46, SE b = 0.11, 95% CI 
−0.68–−0.22, P , 0.001. Although   significant, this 
correlation is weak.
Discussion
We  have  demonstrated  here  that  HRMAS  NMR 
analyses  of  prostate  tissues  can  provide    valuable 
metabolomic information for determining the tumor 
load  in  prostate  tissue  samples.  In  addition,  this 
information  can  be  used  to  establish    relationships 
between  metabolite  levels  and  disease  aggressive-
ness, based on their relations to Gleason score, cell 
  proliferation, and tumor stage. Furthermore, HRMAS 
NMR-derived information appears to be related to 
changes in non-malignant parts of   prostates harbour-
ing tumors that reflect the nature and   proximity of the 
Table 3. Summary of results obtained from the multivariate linear regression analysis. The likelihood of a tissue sample 
containing cancer tissue is significantly positively associated with an increased ratio of (GPCho + Pcho)/cre, and   negatively 
associated with decreased ratios of m-Ino/s-Ino, cho/cre and s-Ino/cre.
Multivariate linear regression dependent: fraction of tumor in per cent (0, 20, 40, 60, 80, 100%)
Metabolite ratios B std. error P 95% cI
(gPcho + Pcho)/cre 44.19 5.16 0.000 33.99 54.40
m-lno/s-lno −4.37 1.23 0.001 −6.81 −1.90
cho/cre −5.72 2.22 0.011 −10.12 −1.32
s-lno/cre −23.24 8.69 0.008 −39.42 −6.16
note: r2 = 0.45. Std. err. Adj. for clustering.
Table 2. Mean metabolite ratios (±SD) of prostate tissue 
samples  according  to  gleason  score:  malignant  gS  6 
(n = 27) vs. malignant gS 7 (n = 14), and non-malignant 
tissue adjacent to gS 6 (n = 85) vs. non-malignant tissue 
adjacent to gS 7 (n = 23).
Malignant Gleason  
score
n Mean sD
(gPcho + Pcho)/cre 6 27 1.25 0.57
7 14 1.74 0.81
cho/cre 6 27 1.71 1.87
7 14 2.34 1.86
cit/cre 6 27 1.56 0.61
7 14 0.93 0.51
m-lno/s-lno 6 27 5.34 1.75
7 14 4.28 1.55
m-lno/cre 6 27 2.01 0.36
7 14 2.03 0.49
non-malignant
(gPcho + Pcho)/cre 6 85 0.84 0.22
7 23 0.92 0.33
cho/cre* 6 85 1.08 0.32
7 23 1.41 0.89
cit/cre 6 85 1.33 0.70
7 23 1.47 0.88
m-lno/s-lno* 6 85 6.07 1.41
7 23 4.08 1.22
m-lno/cre 6 85 2.16 0.48
7 23 1.99 0.36
notes: Std. err. Adj. for clustering, *P  0.05.Stenman et al
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tumors. Thus, such analysis could provide a powerful 
complementary means to examine diagnostic pros-
tate needle biopsies, as suggested by van Asten and 
co-workers.22
In addition, malignant and non-malignant samples 
can be discriminated using the differences between 
them  in  spectral  ratios  of  GPCho  +  PCho23  and 
Cre,21 as previously reported. Since they vary much 
less between stromal and glandular tissues, choline 
compounds (CC) are more useful for this purpose 
than  citrate,  which  generally  accumulates  more  in 
normal prostate epithelial cells than in both stroma 
and cancer cells.24,25 Furthermore, statistical analyses 
involving citrate levels, particularly ratios between 
citrate  and  other  metabolites,  are  complicated  by 
its  variability,  especially  if  some  samples  have 
spectroscopically baseline levels so ratios have close 
to infinite values.21,24,26 The variability and practical 
consequences of citrate were observed in our study, 
since  the  logistic  regression  analysis  showed  the 
Cit/Cre ratio to be significantly (P = 0.010) related 
to  aggressiveness  (tumor  Gleason  score)  without 
adjusting for clustering, but non-significantly related 
(P = 0.081) after adjusting for clustering. Compared 
to citrate, the other biomarker and biomarker ratios 
tested  in  this  study  appeared  to  be  more  robust, 
which  is  clearly  essential  for  biomarkers  that  are 
to  be  used  clinically,  since  prostate  biopsies  have 
varying  morphologies,  stroma  to  epithelium  ratios 
and pathologies, in addition to variations associated 
with cancer.15
Thus,  the  prostate  gland  is  a  challenging  organ 
to study, and detailed knowledge of its structure and 
pathology as well as metabolism is essential when 
interpreting MR spectra.21,27 Furthermore, an important 
feature of PCa is that malignant cells often infiltrate 
among  non-malignant  glands  so  “tumor  samples”, 
such as those examined in this study, that may be 
assumed to be pure tumor according to their position 
in a   whole-mount section, often prove to be mixtures 
of  malignant  and  non-malignant  tissues  on  closer 
  examination. Small increases in the (GPCh + PCho)/
Cre ratio proved, in this study, to be valuable indicators 
of the presence and fraction of cancer cells, as can be 
seen in Tables 1 and 3. A previous breast cancer study 
showed  that  GPCho  and  PCho  resonances  can  be 
separated using high-field (600 Mhz) HRMAS NMR, 
and that increases in PCho relative to Cho are indica-
tive of cancer.28 Our study did not allow such detailed 
exploration of the prostate tissue samples, due to the 
broad range in tumor load in the 41 malignant speci-
mens (Fig. 2). Therefore, an increase in the   spectral 
  resolution  might  have  added  further  diagnostic 
strength to the correlations between bio-markers and 
tumor load in our study. The (GPCh + PCho)/Cre ratio 
proved to have additional strengths as an indicator for 
PCa as it correlated weakly, but significantly, to the 
Ki67 index (and thus tumor cell proliferation) in our 
study. However, to verify our findings and validate 
their use in clinical diagnostics, studies including a 
larger number of patients and specimens with a wider 
range of tumor morphologies are required.
Increases  in  choline  compounds,  probably  due 
to increased turnover of cell membranes, are well 
known markers of cancer,15,28,29 particularly cancers 
with high Gleason scores.30 The Gleason score is the 
best   prognostic indicator currently available,31 thus 
it  is  of  great  interest  to  assess  robust    biomarkers 
which  relate  to  PCa  aggressiveness  graded  by 
the GS. Spectroscopic biomarkers with   correlative 
properties  to  aggressiveness  include  choline  com-
pounds  (CC),  Cit/Cre,  Cho/Cre,  (tCho  +  Cre)/Cit 
and  tCho/Cre.15,22,29,32  However,  according  to  our 
  multivariate analysis, after adjusting for   clustering 
the  biomarker  that  proved  to  be  the  strongest 
  potential candidate for differentiating between GS 6 
and 7   tissues was the Cit/Cre ratio, not a CC. This 
observation corroborated findings from a previous 
examination of prostate   needle biopsies.22
We have recently published indications that pros-
tate tumors in both experimental models and patients 
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Figure  2.  Box-Plot  graph  depicting  the  correlation  between  the 
(gPcho + Pcho)/cre metabolite ratio and the fraction of cancer tissue in 
the prostate samples.hrMAS nMr analysis of intact Pca tissues
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influence  the  surrounding  non-malignant    prostate 
  tissue, and that the strength of this influence is related 
to tumor size and aggressiveness.17 Thus, the   prostate 
appears  to  be  “tinted”  by  the  presence  and  nature 
of cancer elsewhere in the organ, and we   proposed 
that this indication of cancer in non-malignant   tissue 
can  be  named  “TINT”.  Other  investigators  have 
  suggested that observed alterations in   non-malignant 
tissue   surrounding prostate tumors are the result of a 
  “cancer field” effect.33 In the present study we found 
that HRMAS NMR can detect changes in   m-Ino/  s-Ino, 
and Cho/Cre ratios in non-malignant tissue that are 
related to disease aggressiveness, i.e., changes that 
can  differentiate  between  samples  from    prostates 
with  relatively  indolent  Gleason  score  6  or  more 
  aggressive Gleason score 7 tumors.34   Moreover, the 
spectral ratios of (GPCho + PCho)/Cre and m-Ino/ 
s-Ino  in  non-malignant  samples  were  weakly,  but 
  significantly,  jointly  related  to  the  distance  to  the 
nearest tumor in the prostate gland. This is poten-
tially important since needle biopsies are taken from 
the  organ  when    prostate  cancer  is  suspected,  as  a 
result of symptoms and or increased serum PSA, but 
  prostate tumors are difficult to visualize using   current 
imaging techniques so biopsies may miss the tumor. 
Indeed prostate biopsies from at least 75% of all men 
with prostate tumors show no signs of   cancer.17 If, 
however, it was possible to detect changes in such 
apparently  normal  biopsies,  using  HRMAS  NMR 
or other methods, we may be able to predict the risk 
that an aggressive tumor is present elsewhere in the 
organ and, hence, the need for additional biopsies. 
Interestingly, a previous study has also suggested that 
clinical MRS examination of non-malignant parts of 
the prostate can be used to determine prostate cancer 
aggressiveness.29
Another  potentially  interesting  NMR-detectable 
biomarker identified in our multivariate analysis was 
the  dietary  phytochemical,  anti-oxidant,    osmolyte, 
and carbohydrate inositol.35 Inositol, or myo-inositol, 
and its various biochemical derivatives, are readily 
found in mammalian cells and organs, including the 
brain,  kidney,  secretory  tissues,  testis,    epididymal, 
vesicular,  and  prostatic  fluid,  and  is  involved  in 
various  aspects  of  reproduction.35–38    Myo-inositol 
is  synthesized  from  glucose  6-phosphate  by 
  myo-inositol-3-phosphate synthase (IP synthase) in 
most tissues, however, there are several IP synthase 
isoforms, in both rats and humans, suggesting that 
inositol biosynthesis by IP synthase is a highly regu-
lated and multifaceted process.38
Myo-inositol  is  the  parent  compound  of  phytic 
acid, or inositol hexaphosphate (IP6). Jointly, these 
compounds, which are readily found in legumes, and 
fibre-rich foods, have received much   attention lately 
due to their potential anti-carcinogenic and protective 
properties,  both  general39,40  and  specifically  for 
PCa.41–44 Scyllo-inositol, also detected in our study, 
is a myo-Inositol isomer that (interestingly) is under 
investigation for its potential use following deriva-
tization as a novel Positron   Emission   Tomography 
(PET)  radiotracer,  [18F]-1-deoxy-1-fluoro-scyllo-
inositol,  for  both  breast  cancer  and  Alzheimer’s 
  disease (AD).44,45 Both scyllo-inositol and myo-inos-
itol are components of the prostate metabolite pro-
file  generated  by  HRMAS  NMR15  and  profiles  of 
both lung tumors46 and colon cancer.47   However, the 
m-Ino/s-Ino ratio has not been previously   studied, to 
our knowledge, although our findings indicate that it 
is negatively correlated with aggressiveness   (in non-
  malignant prostate tissue samples) and tumor load and, 
conversely, positively correlated to non-  malignancy. 
Hence,  malignancy  appears  to  be  associated  with 
reductions in the concentration of myo-Inositol and/
or increases in the concentration of scyllo-Inositol 
(Fig. 1A–1C).
conclusions
The 1H HRMAS NMR approach appears to have the 
potential to determine if a cancer may be   present in the 
proximity of non-malignant prostate tissue biopsies. 
In addition, analysis of prostate tissue samples can be 
used to determine the fraction of tumor cells in a pros-
tate tissue biopsy. Further explorations of additional 
HRMAS NMR detectable metabolites are needed to 
increase the capacity to distinguish different types of 
samples and to elucidate the potential of using spec-
troscopic biomarkers that can be examined clinically 
in the future.
Acknowledgements
Support by the Lion’s Cancer Research Foundation 
(grant  no.   AMP08-565),  Umeå  University,  the 
Swedish Cancer Foundation and Swedish Research 
Council is gratefully acknowledged. Thanks are due 
to  Birgitta  Ekblom,  Elisabeth  Dahlberg,    Pernilla Stenman et al
46  Biomarker Insights 2011:6
  Andersson (Dept. of Medical Biosciences, Pathology), 
Kerstin  Almroth  and  Britt-Inger  Dahlin  (Dept.  of 
  Surgical and Perioperative Sciences).
Abbreviations
HRMAS,  high-resolution  magic  angle  spinning; 
NMR,  nuclear  magnetic  resonance;  PCa,  prostate 
  cancer;  (GPCho  +  PCho),  glycerophosphorylch
oline  +    phosphorylcholine;  Cho,  choline;  m-Ino, 
  myo-inositol;  s-Ino,  scyllo-inositol;  Cre,  creatine; 
Cit, citrate.
Disclosure
This  manuscript  has  been  read  and  approved  by 
all authors. This paper is unique and is not under 
consideration  by  any  other  publication  and  has 
not  been  published  elsewhere.  The  authors  and 
peer reviewers of this paper report no conflicts of 
  interest. The authors confirm that they have permis-
sion to reproduce any copyrighted material.
References
  1.  Thun MJ, DeLancey JO, Center MM, Jemal A, Ward EM. The global burden 
of cancer: priorities for prevention. Carcinogenesis. 2010;31(1):100–10.
  2.  Wolf AMD, Wender RC, Etzioni RB, Thompson IM, D’Amico AV, et al. 
American Cancer Society Guideline for the Early Detection of Prostate 
Cancer. CA Cancer J Clin. 2010;60:70–98.
  3.  Chrouser KL, Lieber MM. Extended and saturation needle biopsy for the 
diagnosis of prostate cancer. Curr Urol Rep. 2004;5(3):226–30.
  4.  Fleshner N, Klotz L. Role of “saturation biopsy” in the detection of prostate 
cancer among difficult diagnostic cases. Urology. 2002;60:93–7.
  5.  Baccala AA, Moussa AS, Elbary AA, et al. Risk factors and predictors of 
prostate cancer in men with negative repeat saturation biopsy. Uro Today Int J. 
2010;3(1).
  6.  Tessem  MB,  Selnaes  KM,  Sjursen W,  et  al.  Discrimination  of  patients 
with  microsatellite  instability  colon  cancer  using  1H  HR  MAS  MR 
spectroscopy  and  chemometric  analysis.  J  Proteome  Res.  2010;9(7): 
3664–70.
  7.  Santos  CF,  Kurhanewicz  J,  Tabatabai  ZL,  et  al.  Metabolic,  pathologic,   
and  genetic  analysis  of  prostate  tissues:  quantitative  evaluation  of 
histopathologic and mRNA integrity after HR-MAS spectroscopy. NMR 
Biomed. In press.
  8.  Levin YS, Mark J. Albers MJ, et al. Methods for metabolic evaluation 
of prostate cancer cells using proton and  13C HR-MAS spectroscopy and 
[3–13C]  pyruvate  as  a  metabolic  substrate.  Magn  Reson  Med.  2009;62: 
1091–8.
  9.  Shukla-Dave A, Hricak H, Ishill N, et al. Prediction of prostate cancer 
recurrence using magnetic resonance imaging and molecular profiles. Clin 
Cancer Res. 2009;15(11):3842–9.
  10.  Lange  T,  Schulte  RF,  Boesiger  P.  Quantitative  J-resolved  prostate 
spectroscopy using two-dimensional prior-knowledge fitting. Magn Reson 
Med. 2008;59(5):966–72.
  11.  Cheng LL, Lean CL, Bogdanova A, et al. Enhanced resolution of proton 
NMR spectra of malignant lymph nodes using magic-angle spinning. Magn 
Reson Med. 1996;36:653–8.
  12.  Sitter B, Sonnewald U, Spraul M, Fjösne H, Gribbestad IS. High-resolution 
magic angle spinning MRS of breast cancer tissue. NMR Biomed. 2002; 
15(5):327–37.
  13.  Beckonert B, Coen M, Keun HC, et al. High-resolution   magic-angle-spinning 
NMR  spectroscopy  for  metabolic  profiling  of  intact  tissues.  Nature 
Protocols. 2010;5:1019–32.
  14.  Gleason  DF,  Mellinger  GT.  Prediction  of  prognosis  for  prostatic 
adenocarcinoma  by  combined  histological  grading  and  clinical  staging.   
J Urol. 1974;111:58–64.
  15.  Swanson  MG,  Vigneron  DB,  Tabatabai  ZL,  et  al.  Proton  HR-MAS 
spectroscopy and quantitative pathologic analysis of MRI/3D-MRSI tar-
geted post-surgical prostate tissues. Magn Reson Med. 2003;50(5):944–54.
  16.  Josefsson A, Wikström P, Granfors T, et al. Tumor size, vascular density 
and proliferation as prognostic markers in GS 6 and GS 7 prostate tumors 
in patients with long follow-up and non-curative treatment. Eur Urol. 2005; 
48(4):577–83.
  17.  Halin S, Hammarsten P, Adamo H, Wikstrom P, Bergh A. Tumor indicating 
normal tissue (TINT) could be a novel source of diagnostic and prognos-
tic markers for prostate cancer. Expert Opinion on Medical Diagnostics, 
2011,5(01):37–47.
  18.  Meiboom  S,  Gill  D.  Modified  spin-echo  method  for  measuring  nuclear 
relaxation times, Rev. Sci Instrum. 1958;29:688–91.
  19.  Jordan KW, He W, Halpern EF, Wu C-L, Cheng LL. Evaluation of tissue 
metabolites with high resolution magic angle spinning MR spectroscopy 
human  prostate  samples  after  three-year  storage  at  −80  °C.  Biomarker 
Insights. 2007;2:147–54.
  20.  Stenman  K,  Hauksson  JB,  Gröbner  G,  Stattin  P,  Bergh A,  Riklund  K. 
Detection  of  polyunsaturated  omega-6  fatty  acid  in  human  malignant 
  prostate tissue by 1D and 2D high-resolution magic angle spinning NMR 
spectroscopy. MAGMA. 2009;22(6):327–31.
  21.  Stenman K, Surowiec I, Antti H, et al. Detection of local prostate metabo-
lites by HRMAS NMR spectroscopy: A comparative study of human and rat 
prostate tissues. Magnetic Resonance Insights. 2010;4:27–41.
  22.  Van Asten J, Cuijpers V, Hulsbergen-van de Kaa C, et al. High resolution 
magic  angle  spinning  NMR  spectroscopy  for  metabolic  assessment  of 
  cancer presence and Gleason score in human prostate needle biopsies. Magn 
Reson Mater Phy. 2008;21:435–42.
  23.  Swanson MG, Zektzer AS, Tabatabai ZL, et al. Quantitative analysis of 
prostate metabolites using  1H HR-MAS spectroscopy. Magn Reson Med. 
2006;55(6):1257–64.
  24.  Swindle P,  McCredie S,  Russell P,  et  al. Pathologic characterization of 
human prostate tissue with proton MR spectroscopy. Radiology. 2003;228: 
144–51.
  25.  Singh  KK,  Desouki  MM,  Franklin  RB,  Costello  LC.  Mitochondrial 
  aconitase and citrate metabolism in malignant and nonmalignant human 
prostate   tissues. Mol Cancer. 2006;5:14.
  26.  McLean MA, Barrett T, Gnanapragasam VJ, et al. Prostate cancer metabolite 
quantification relative to water in 1H-MRSI in vivo at 3 Tesla. Magn Reson 
Med. In print. 2010.
  27.  Swindle P, Ramadan S, Stanwell P, McCredie S, Russell P, Mountford C. 
Proton magnetic resonance spectroscopy of the central, transition and periph-
eral zones of the prostate: assignments and correlation with histopathology. 
Magn Reson Mater Phy. 2008;21:423–34.
  28.  Sitter B, Lundgren S, Bathen TF, Halgunset J, Fjosne HE, Gribbestad IS. 
Comparison of HR MAS MR spectroscopic profiles of breast cancer tissue 
with clinical parameters. NMR Biomed. 2006;19:30–40.
  29.  Cheng LL, Burns MA, Taylor JL, et al. Metabolic characterization of human 
prostate  cancer  with  tissue  magnetic  resonance.  Cancer  Res.  2005;65: 
3030–4.
  30.  Kurhanewicz J, Swanson MG, Nelson SJ, Vigneron DB. Combined   magnetic 
resonance imaging and spectroscopic imaging approach to molecular imag-
ing of prostate cancer. J Magn Reson Imaging. 2002;16:451–63.
  31.  Kelloff GJ, Choyke P, Coffey DS. Challenges in clinical prostate cancer: 
Role of Imaging AJR. 2009;192:1455–70.
  32.  Zakian KL, Sircar K, Hricak H, Chen H-N, Shukla-Dave A, Eberhardt S. 
Correlation of proton MR Spectroscopic Imaging with Gleason Score Based 
on Step-Section Pathologic Analysis after Radical Prostatectomy. Radiology. 
2005;234:804–14.
  33.  Nonn L, Ananthanarayanan V, Gann PH. Evidence for field cancerization of 
the prostate. Prostate. 2009;69(13):1470–9.publish with Libertas Academica and 
every scientist working in your field can 
read your article 
“I would like to say that this is the most author-friendly 
editing process I have experienced in over 150 
publications. Thank you most sincerely.”
“The communication between your staff and me has 
been terrific.  Whenever progress is made with the 
manuscript, I receive notice.  Quite honestly, I’ve 
never had such complete communication with a 
journal.”
“LA is different, and hopefully represents a kind of 
scientific publication machinery that removes the 
hurdles from free flow of scientific thought.”
Your paper will be:
•  Available to your entire community 
free of charge
•  Fairly and quickly peer reviewed
•  Yours!  You retain copyright
http://www.la-press.com
hrMAS nMr analysis of intact Pca tissues
Biomarker Insights 2011:6  47
  34.  Egevad L, Granfors T, Karlberg L, Bergh A, Stattin P. Prognostic value of 
the Gleason score in prostate cancer. BJU Int. 2002;89(6):538–42.
  35.  Patricia Beemster P, Groenen P, Steegers-Theunissen R. Involvement of 
inositol in reproduction. Nutrition Reviews. 2002;60(3):80–7.
  36.  Lewin LM, Yannai Y, Sulimovici S, Kraicer PF. Studies on the metabolic 
role of myo-inositol. Distribution of radioactive myo-inositol in the male 
rat. Biochem J. 1976;156:375–80.
  37.  Mann T. Secretory function of the prostate, seminal vesicle and other male 
accessory organs of reproduction. J Reprod Fert. 1974;37:179–88.
  38.  Seelan RS, Lakshmanan J, Casanova MF, Parthasarathy RN. Identification 
of myo-inositol-3-phosphate synthase isoforms. Characterization, expression, 
and putative role of a 16-kDa γc isoform. JBC. 2009;284:9443–57.
  39.  Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate 
(IP6) and inositol: from laboratory to clinic. J Nutr. 2003;133(11 Suppl 1): 
3778S–84.
  40.  Bacić I, Druzijanić N, Karlo R, Skifić I, Jagić S. Efficacy of IP6 + inositol in 
the treatment of breast cancer patients receiving chemotherapy: prospective, 
randomized, pilot clinical study. J Exp Clin Cancer Res. 2010;29:12.
  41.  Singh  RP,  Agarwal  C,  Agarwal  R.  Inositol  hexaphosphate  inhibits 
growth, and induces G1 arrest and apoptotic death of prostate carcinoma 
DU145 cells: modulation of CDKI-CDK-cyclin and pRb-related protein-
E2F complexes. Carcinogenesis. 2003;24(3):555–63.
  42.  Singh  RP,  Sharma  G,  Mallikarjuna  GU,  Dhanalakshmi  S,  Agarwal  C, 
  Agarwal  R.  In  vivo  suppression  of  hormone-refractory  prostate  cancer 
growth by inositol hexaphosphate. Induction of insulin-like growth factor 
binding protein-3 and inhibition of vascular endothelial growth factor. Clin 
Cancer Res. 2004;10:244.
  43.  Roy S, Gu M, Ramasamy K, et al. p21/Cip1 and p27/Kip1 are essential 
molecular targets of inositol hexaphosphate for its antitumor efficacy against 
prostate cancer. Cancer Res. 2009;69(3):1166–73.
  44.  Gu M, Roy S, Raina K, Agarwal C, Agarwal R. Inositol hexaphosphate 
  suppresses growth and induces apoptosis in prostate carcinoma cells in 
culture and nude mouse xenograft: PI3K-Akt pathway as potential target. 
Cancer Res. 2009;69(24):9465–72.
  45.  Vasdev  N,  Chio  J,  van  Oosten  EM,  et  al.  Synthesis  and  preliminary 
  biological  evaluations  of  [18F]-1-deoxy-1-fluoro-scyllo-inositol.  Chem 
Commun (Camb). 2009;(37):5527–9.
  46.  Pimlott  SL,  Sutherland  A.  Molecular  tracers  for  the  PET  and  SPECT 
  imaging of disease. Chem Soc Rev. 2011;40(1):149–62.
  47.  Duarte IF, Rocha CM, Barros AS, Gil AM, Goodfellow BJ, Carreira IM, 
et al. Can nuclear magnetic resonance (NMR) spectroscopy reveal different 
metabolic signatures for lung tumors? Virchows Arch. 2010;457:715–25.